Acutaas Chemicals Limited vs Rubicon Research Limited
An objective side-by-side of ACUTAAS and RUBICON, both in Pharmaceuticals: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-09-28 close
Latest results: ACUTAAS Jun 2026 · RUBICON Jun 2026
At a glance
- Acutaas Chemicals Limited is the larger company by market value, about 1.0 times the size of Rubicon Research Limited.
- On trailing earnings, Rubicon Research Limited trades at the lower P/E (124.4 against 137.9).
| Metric | Acutaas Chemicals ACUTAAS |
Rubicon Research RUBICON |
|---|---|---|
| Size and price | ||
| Market cap | ₹26,317 Cr | ₹26,296 Cr |
| Share price | ₹3,214 | ₹1,593 |
| Valuation | ||
| P/E | 137.89 | 124.37 |
| Profitability | ||
| Operating margin | 48.7% | 23.3% |
| Sales (TTM) | ₹843 Cr | ₹1,422 Cr |
| Net profit (TTM) | ₹191 Cr | ₹211 Cr |
| Growth | ||
| Latest quarter sales YoY | +59.1% | — |
| Latest quarter profit YoY | +70.4% | — |
| Financial strength | ||
| Interest cover | 122.09 | — |
| Ownership | ||
| Promoter holding | — | 59.8% |
| Promoter change (4 qtrs) | — | +0.00 pp |
| Price performance | ||
| Return 1M | -3.45% | -13.48% |
| Return 3M | -8.84% | +13.54% |
| Return 1Y | +120.12% | — |
| Return YTD | +88.54% | +133.98% |
| Technical condition | ||
| Technical score | 45 | 26 |
| RS rating (1-99) | 89.00 | 94.00 |
| % vs 200-DMA | +21.79% | +44.16% |
| RSI (14) | 46.35 | 35.54 |
| % from 52-week high | -14.05% | -16.12% |
